Effective Early Treatment of AChR Antibody-Positive Myasthenia Gravis with Rituximab; the Experience from a Neuroimmunology Clinic in a Developing Country

BACKGROUND: Rituximab is reserved for treating refractory myasthenia gravis (MG) patients. Here we report our experience with rituximab in AChR antibody positive generalized MG (gMG) and impending myasthenic crisis (IMC). METHODS: This retrospective, observational study, conducted at a tertiary care...

Descripción completa

Detalles Bibliográficos
Autores principales: Mathew, Thomas, Thomas, Kurian, K John, Saji, Venkatesh, Shruthi, Nadig, Raghunandan, Badachi, Sagar, Souza, Delon D, Sarma, GRK, Parry, Gareth J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8135199/
https://www.ncbi.nlm.nih.gov/pubmed/34045914
http://dx.doi.org/10.1177/11795735211016080

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8135199/
https://www.ncbi.nlm.nih.gov/pubmed/34045914
http://dx.doi.org/10.1177/11795735211016080

Ejemplares similares